Most Read Articles
13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.
12 Jun 2020
Drawing from experience as a key investigator in landmark clinical trials (including PALOMA, MONALEESA and MONARCH), and his clinical experience with CDK4/6 inhibitors, Dr Rafael Villanueva Vázquez shares his insights into the current evidence of using CDK4/6 inhibitors to treat HR+/HER2- ABC.
Roshini Claire Anthony, 6 days ago

Female cancer survivors who undergo fertility preservation before cancer treatment often use their stored gametes/embryos. This highlights the effectiveness of pre-cancer fertility preservation, according to a study presented at ESHRE 2020.

 

Cardiovascular risk higher in men with prostate cancer

25 May 2020
Prostate cancer is a silent killer. Many may not be aware of the illness until it is too late.

About two in three men with prostate cancer are at increased cardiovascular (CV) risk, suggests a recent study. A positive association exists between a plan to use androgen deprivation therapy and baseline CV risk factors, but such link is explained by confounding factors.

The authors described the CV risk profile in a representative cohort of patients with prostate cancer treated with or without androgen deprivation therapy. A total of 2,492 consecutive men (mean age, 68 years) with prostate cancer (newly diagnosed or with a plan to prescribe androgen deprivation therapy for the first time) from 16 Canadian sites were included. The Framingham risk scores were calculated to estimate the CV risk.

Ninety-two percent of men had new prostate cancer (intermediate risk, 41 percent; high risk, 50 percent). Twelve percent only had primary school as the highest level of education achieved. More than half of the participants (58 percent) were current or former smokers, while 22 percent had known CV disease, 16 percent had diabetes, 45 percent had hypertension, 31 percent had body mass index 30 kg/m2, and 24 percent had low levels of physical activity. Mean handgrip strength was 37.3 kg.

Sixty-nine percent of men had a Framingham risk score consistent with high CV risk. Framingham risk scores were higher among participants in whom androgen deprivation therapy was planned than those not intending to receive the said treatment. Of note, such risk disappeared after adjustment for confounders.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.
12 Jun 2020
Drawing from experience as a key investigator in landmark clinical trials (including PALOMA, MONALEESA and MONARCH), and his clinical experience with CDK4/6 inhibitors, Dr Rafael Villanueva Vázquez shares his insights into the current evidence of using CDK4/6 inhibitors to treat HR+/HER2- ABC.
Roshini Claire Anthony, 6 days ago

Female cancer survivors who undergo fertility preservation before cancer treatment often use their stored gametes/embryos. This highlights the effectiveness of pre-cancer fertility preservation, according to a study presented at ESHRE 2020.